指南与共识呼吸衰竭与机械通气重症综合管理与镇静镇痛

COVID-19相关肺曲霉病的诊断与临床管理特别工作组报告

Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis.
PubMed 文献 · Intensive Care Med · 2021-06-23
一句话结论CAPA患病率0–33%,支气管镜和BAL是诊断基石,血清标志物85%阴性,死亡率约50%,推荐对BAL阳性患者抗真菌治疗,不建议常规停用糖皮质激素或IL-6阻断治疗。

该特别工作组由28名国际专家组成,采用GRADE方法制定COVID-19相关肺曲霉病(CAPA)的诊断与管理推荐。CAPA患病率0–33%,可能部分因病例定义不同,但可能反映真实差异。支气管镜和支气管肺泡灌洗(BAL)仍是诊断基石,可诊断侵袭性曲霉气管支气管炎并获取最佳验证标本。多数CAPA患者缺乏传统宿主因素,但既往结构性肺病和免疫调节治疗可能增加风险。CT对排除或确认CAPA价值似乎有限,血清生物标志物在85%患者中阴性。CAPA死亡率约50%,推荐对BAL阳性患者进行抗真菌治疗,但治疗决策取决于患者临床状况和机构CAPA发生率;不建议在CAPA患者中常规停用伴随的糖皮质激素或IL-6阻断治疗。

要点

  • CAPA患病率0–33%,可能部分因病例定义不同,但可能反映真实差异。
  • 支气管镜和BAL是CAPA诊断基石,可诊断侵袭性曲霉气管支气管炎并获取最佳验证标本。
  • 多数CAPA患者缺乏传统宿主因素,但既往结构性肺病和免疫调节治疗可能增加风险。
  • CT对排除或确认CAPA价值似乎有限,血清生物标志物在85%患者中阴性。
  • CAPA死亡率约50%,推荐对BAL阳性患者抗真菌治疗,不建议常规停用糖皮质激素或IL-6阻断治疗。

适用人群与场景

  • 重症COVID-19入住ICU的患者。

处置流程与药物剂量

  • 推荐对BAL阳性患者进行抗真菌治疗。
  • 治疗决策取决于患者临床状况和机构CAPA发生率。
  • 不建议在CAPA患者中常规停用伴随的糖皮质激素或IL-6阻断治疗。

研究设计与关键结果

  • CAPA患病率0–33%,可能部分因病例定义不同,但可能反映真实差异。
  • 支气管镜和BAL是诊断基石,可诊断侵袭性曲霉气管支气管炎并获取最佳验证标本。
  • 多数CAPA患者缺乏传统宿主因素,但既往结构性肺病和免疫调节治疗可能增加风险。
  • CT对排除或确认CAPA价值似乎有限,血清生物标志物在85%患者中阴性。
  • CAPA死亡率约50%。

证据类型、等级与局限

  • 证据类型:国际专家特别工作组报告,采用GRADE方法制定推荐。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对重症COVID-19入住ICU患者,支气管镜和BAL是诊断CAPA的基石。
  • 对BAL阳性CAPA患者推荐抗真菌治疗,决策需结合临床状况和机构CAPA发生率。
  • 不建议在CAPA患者中常规停用糖皮质激素或IL-6阻断治疗。

指南或共识出处

  • Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis(Intensive Care Med)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Invasive pulmonary aspergillosis (IPA) is increasingly reported in patients with severe coronavirus disease 2019 (COVID-19) admitted to the intensive care unit (ICU). Diagnosis and management of COVID-19 associated pulmonary aspergillosis (CAPA) are challenging and our aim was to develop practical guidance.

METHODS: A group of 28 international experts reviewed current insights in the epidemiology, diagnosis and management of CAPA and developed recommendations using GRADE methodology.

RESULTS: The prevalence of CAPA varied between 0 and 33%, which may be partly due to variable case definitions, but likely represents true variation. Bronchoscopy and bronchoalveolar lavage (BAL) remain the cornerstone of CAPA diagnosis, allowing for diagnosis of invasive Aspergillus tracheobronchitis and collection of the best validated specimen for Aspergillus diagnostics. Most patients diagnosed with CAPA lack traditional host factors, but pre-existing structural lung disease and immunomodulating therapy may predispose to CAPA risk. Computed tomography seems to be of limited value to rule CAPA in or out, and serum biomarkers are negative in 85% of patients. As the mortality of CAPA is around 50%, antifungal therapy is recommended for BAL positive patients, but the decision to treat depends on the patients' clinical condition and the institutional incidence of CAPA. We recommend against routinely stopping concomitant corticosteroid or IL-6 blocking therapy in CAPA patients.

CONCLUSION: CAPA is a complex disease involving a continuum of respiratory colonization, tissue invasion and angioinvasive disease. Knowledge gaps including true epidemiology, optimal diagnostic work-up, management strategies and role of host-directed therapy require further study.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Verweij PE, Brüggemann RJM, Azoulay E, et al. Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. Intensive Care Med. 2021. PMID: 34160631. doi:10.1007/s00134-021-06449-4

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。